Hematologist-Oncologist Salary Guide 2026: Chemo Buy-and-Bill, wRVU & Pay by Setting

Hematology-oncology is among the highest-compensated internal medicine fellowships, and the gap between employed health system and private community oncology compensation is larger than in almost any other physician specialty. The primary driver is chemotherapy and targeted therapy buy-and-bill revenue — a mechanism that allows physician-owned community oncology practices to generate substantial income from the margin between what they pay for cancer drugs and what payers reimburse. In 2026, employed hematologist-oncologists in health system positions typically earn $380,000–$580,000, while productive community oncologists with infusion center ownership can reach $600,000–$750,000 or more. This guide covers the full compensation spectrum including buy-and-bill economics, academic pay, bone marrow transplant specialist income, and the pharmaceutical industry alternative.

Hematologist-oncologist salary by setting

• Community oncology / private practice (with infusion center): $450,000–$750,000; the income premium over employed settings is almost entirely driven by chemotherapy and targeted therapy buy-and-bill revenue; physician-owned or physician-partnership community oncology groups that have invested in infusion infrastructure, oncology pharmacy staffing, and payer contracting consistently outpay employed health system models by $100,000–$250,000+
• Employed hematologist-oncologist (health system): $380,000–$580,000; salary + wRVU productivity bonus; health system captures infusion revenue; employed model growing as large health systems acquire independent oncology practices; base salary is higher than most internal medicine subspecialties due to complexity billing and relative specialty scarcity
• Academic hematology-oncology (medical school faculty): $290,000–$420,000; lowest nominal pay but significantly supplemented by NIH R01/K-series grant funding for active investigators; subspecialty clinical and research focus (leukemia, lymphoma, myeloma, solid tumor oncology); clinical trial management adds complexity and sometimes separate compensation through research infrastructure
• Pure hematology (non-malignant, academic or employed): $280,000–$380,000; benign hematology subspecialty (sickle cell, hemophilia, ITP, thrombophilia, anticoagulation management); fewer oncology drug revenues; increasing demand as hemophilia gene therapy and sickle cell CRISPR therapies require expert management
• Bone marrow transplant (BMT) / stem cell transplant specialist: $360,000–$520,000; inpatient-heavy; complex immunosuppression management; high call intensity; concentrated in large academic medical centers and designated BMT programs; Cell therapy (CAR-T) expertise increasingly valued
• Pharmaceutical / biotech medical director (oncology): $350,000–$600,000 base + significant bonus and equity; medical affairs director at oncology-focused pharmaceutical companies (Bristol-Myers Squibb, AstraZeneca, Pfizer oncology, smaller biotech); MSL leadership; clinical trial design; drug development advisory
• Radiation oncology: Separate specialty from medical oncology; technical component revenue from treatment planning and delivery creates a different compensation model ($380,000–$600,000+ in many settings); not covered in detail in this guide

Chemotherapy buy-and-bill economics

The buy-and-bill model for chemotherapy and targeted therapy is the defining income mechanism of private community oncology. Understanding the economics is essential for any physician evaluating a community oncology opportunity:

• How buy-and-bill works in oncology: The practice purchases chemotherapy drugs from a specialty distributor at ASP (Average Sales Price); administers them in the in-office infusion center; and bills the payer at ASP + 6% (Medicare) or ASP + higher markup (commercial payers); the difference between purchase price and reimbursement is the practice's drug margin
• Drug cost scale: Modern targeted therapies and immunotherapies (checkpoint inhibitors like pembrolizumab/Keytruda, nivolumab/Opdivo; ADCs like trastuzumab deruxtecan; CAR-T adjunct drugs) carry wholesale costs of $8,000–$50,000+ per infusion; even a 4–6% margin on a $20,000 drug represents $800–$1,200 per patient per visit
• Volume scale: A mid-size community oncology group of 4–8 physicians with an active infusion center administering 80–150 infusions/week can generate $3,000,000–$8,000,000+ per year in total infusion revenue (drug + administration); physician owners receive a pro-rata share of net income after practice overhead
• 340B drug pricing program: Federally qualified health centers and certain hospital outpatient departments qualify for 340B drug pricing — significantly reduced acquisition costs that increase buy-and-bill margin; community oncology practices not affiliated with qualifying entities do not have 340B access
• Payer pressure: Site-of-care mandates (requiring patients to receive infusions at hospital outpatient departments or specialty pharmacy rather than in-office) and specialty pharmacy carve-outs are the primary payer tactics threatening community oncology buy-and-bill revenue; aggressive payer contracting and patient advocacy are community oncology's defensive tools

wRVU productivity in hematology-oncology

• Typical wRVU rate: $55–$75/unit; heme/onc is at the higher end of internal medicine subspecialty wRVU rates due to high E&M complexity levels
• Full-time employed heme/onc wRVU output: 4,500–6,500 wRVUs/year; Level 5 new patient visits and complex established visits (chemotherapy management, toxicity assessment, survivorship care) dominate the billing mix
• Chemotherapy administration codes (CPT 96401–96549): Each infusion visit generates professional fee billing for the physician's time and complexity assessment, separate from the drug J-code; these codes add meaningfully to wRVU volume for employed oncologists on productivity models
• Inpatient oncology consultation: Heme/onc hospital consults for new cancer diagnosis, febrile neutropenia, bone marrow biopsy, tumor lysis syndrome, and complex toxicity management add 1,000–2,000 wRVUs/year for oncologists covering hospital services

CAR-T and cell therapy — emerging income dimension

CAR-T cell therapies (axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel, and others) represent the highest-cost medications in hematology-oncology, with single-infusion costs of $300,000–$600,000. The centers administering these therapies (FACT-accredited bone marrow transplant programs) generate significant facility fee revenue; the treating hematologist-oncologist's income is primarily through professional fee billing and program leadership stipends rather than drug margin for most institutional settings. However, as CAR-T programs expand to larger community cancer centers, the physicians leading those programs are negotiating program director stipends of $25,000–$75,000/year above base compensation.

Geographic variation in heme/onc compensation

• Sun Belt / high-growth markets (FL, TX, AZ, NC): $420,000–$700,000; high cancer incidence, aging population, and established community oncology group practice culture; FL and TX are particularly strong community oncology markets
• Coastal academic centers (NYC, Boston, LA, Chicago): $340,000–$500,000 academic/employed; high oncology specialist density; private practice infusion center economics more competitive with hospital-based programs
• Midwest and Southeast: $390,000–$600,000; community oncology practices with infusion programs well-established; rural oncologists covering large geographic catchment areas with less specialist competition
• Rural markets: Some rural oncology positions offer significant sign-on bonuses ($80,000–$150,000) to attract the only oncologist within 60–100 miles, particularly in markets where the local hospital has an infusion center but lacks a supervising oncologist

What we see at Ava Health

Hematology-oncology is one of our higher-volume physician specialty placements, primarily because the compensation gap between employed health system and community oncology models creates a predictable cycle of physician movement — oncologists trained at academic centers evaluate community practice, recognize the income differential, and seek to transition. For heme/onc fellows in our network evaluating their first attending position, the clearest decision framework is: if you want the highest income ceiling and are willing to take on practice business risk, community oncology with infusion ownership is the path; if you want research time, academic prestige, or guaranteed schedule stability, academic or large health system employment is the better match. The financial difference between these paths over a 10-year career is substantial and should be understood before signing any offer.

Related: Internal Medicine Physician Salary Guide, General Surgeon Salary Guide, Endocrinologist Salary Guide, Rheumatologist Salary Guide.